FDA Lifts, Clinical Hold on Genta's Tesetaxel, an Oral Taxane.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 8, p. 929
- Publication type:
- Article
Works matching DE "GENTA Inc."
Results: 11
1
2
Oblimersen Plus Chemotherapy Prolongs Survival in Patients With Relapsed/Refractory CLL Who Achieve Complete Remission.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 1, p. 87
- Publication type:
- Article
3
New Drug Application Filed for Oblimersen in Relapsed Chronic Lymphocytic Leukemia.
- Published in:
- Oncology (08909091), 2005, v. 19, n. 10, p. 1294
- Publication type:
- Article
4
Genasense NDA Withdrawn.
- Published in:
- Bio-IT World, 2004, v. 3, n. 6, p. 10
- By:
- Publication type:
- Article
5
Antisense drugs progressing through product pipelines.
- Published in:
- American Journal of Health-System Pharmacy, 2002, v. 59, n. 21, p. 2046, doi. 10.1093/ajhp/59.21.2046
- Publication type:
- Article
6
CLINICAL TRIALS NEWS.
- Published in:
- Applied Clinical Trials, 2007, v. 16, n. 3, p. 16
- By:
- Publication type:
- Article
7
Trials in progress.
- Published in:
- Applied Clinical Trials, 2003, v. 12, n. 11, p. 14
- Publication type:
- Article
8
Genta Incorporated (GNTA) announces licensing agreement for worldwide development of tesetaxel.
- Published in:
- Expert Review of Anticancer Therapy, 2008, v. 8, n. 4, p. 509
- Publication type:
- Article
9
News In Brief.
- Published in:
- Nature Biotechnology, 2006, v. 24, n. 11, p. 1309, doi. 10.1038/nbt1106-1309
- By:
- Publication type:
- Article
10
Genta sued over NDA withdrawal.
- Published in:
- Nature Biotechnology, 2004, v. 22, n. 7, p. 788, doi. 10.1038/nbt0704-788
- By:
- Publication type:
- Article
11
Genta strikes bumper deal with Aventis.
- Published in:
- Nature Biotechnology, 2002, v. 20, n. 6, p. 533, doi. 10.1038/nbt0602-533b
- By:
- Publication type:
- Article